Investigating the effect of magnesium supplementation on inflammatory factors in patients with acute leukemia

The effects of neutropenic diet with or without Magnesium supplementation on inflammatory factors and outcomes of Allogenic -Hematopoietic stem cell transplantation in patients with acute leukemia : A double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240812062726N1

Enrollment

Registered

2024-09-17

Start date

2025-01-20

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute leukemia. Lymphoid leukemia

Interventions

Intervention 1: Intervention group: Intervention group: The intervention group will receive 1 tablet of magnesium citrate with a dose of 420 mg daily for 21 days after the bone marrow transplant, star

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years Patients with acute leukemia whose disease is confirmed by histopathology Allogeneic transplant candidate admitted to the Bone Marrow Transplant Department of Ayatollah Taleghani Hospital No history of alcohol and drug use Body mass index less than 40 Not taking magnesium supplements in the past month Willingness to cooperate in the study

Exclusion criteria

Exclusion criteria: A serum magnesium level above 2.4 mg Serum magnesium level less than 1.5 mg/dL Patients who are candidates for allogeneic transplantation after autologous transplantation. History of heart, liver, kidney and diabetes diseases

Design outcomes

Primary

Measure	Time frame
Interleukin 6. Timepoint: Upon entering the ward and on the 21st day after transplantation. Method of measurement: ELISA laboratory evaluation.;Tumour Necrosis Factor alpha. Timepoint: Upon entering the ward and on the 21st day after transplantation. Method of measurement: ELISA laboratory evaluation.	—

Secondary

Measure	Time frame
Serum C-reactive protein. Timepoint: When the patient enters the bone marrow transplant department and on the 21st day after the transplant. Method of measurement: Immunoturbidometry method in terms of mg/liter.;Serum erythrocyte sedimentation rate. Timepoint: When the patient enters the bone marrow transplant department and on the 21st day after the transplant. Method of measurement: Automated Modified Westergren.;Incidence of Graft-versus-host disease (GVHD). Timepoint: Length of hospitalization after transplantation in the bone marrow transplant department. Method of measurement: Checking the patient's file.;Type and severity of GVHD. Timepoint: Length of hospitalization after transplantation in the bone marrow transplant department. Method of measurement: Clinical tests of the patient or the occurrence of diarrhea or observing the occurrence of skin manifestations.;Getting a fever. Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: Information contained in the patient's file.;Getting an infection. Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: Information contained in the patient's file.;Mortality not related to recurrence ( NRM ). Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: contact with the patient or first-degree relatives.;The duration of the transplant. Timepoint: The number of days between the injection of stem cells until the number of neutrophils reaches 1500. Method of measurement: Information contained in the patient's file.	—

Measure

Time frame

Serum C-reactive protein. Timepoint: When the patient enters the bone marrow transplant department and on the 21st day after the transplant. Method of measurement: Immunoturbidometry method in terms of mg/liter.;Serum erythrocyte sedimentation rate. Timepoint: When the patient enters the bone marrow transplant department and on the 21st day after the transplant. Method of measurement: Automated Modified Westergren.;Incidence of Graft-versus-host disease (GVHD). Timepoint: Length of hospitalization after transplantation in the bone marrow transplant department. Method of measurement: Checking the patient's file.;Type and severity of GVHD. Timepoint: Length of hospitalization after transplantation in the bone marrow transplant department. Method of measurement: Clinical tests of the patient or the occurrence of diarrhea or observing the occurrence of skin manifestations.;Getting a fever. Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: Information contained in the patient's file.;Getting an infection. Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: Information contained in the patient's file.;Mortality not related to recurrence ( NRM ). Timepoint: Duration of hospitalization in the bone marrow transplant department. Method of measurement: contact with the patient or first-degree relatives.;The duration of the transplant. Timepoint: The number of days between the injection of stem cells until the number of neutrophils reaches 1500. Method of measurement: Information contained in the patient's file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Sadat Zahedi

Shahid Beheshti University of Medical Sciences

Hoda.s.zahedi@gmail.com+98 21 2560 2243

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026